South Korea-based Samsung Biologics and American pharma firm Pfizer have recently announced a strategic partnership aimed at the long-term commercial manufacturing of Pfizer's diverse portfolio of products.

According to the terms of this agreement, Samsung Biologics will offer Pfizer additional capacity to meet the demands of a multi-product biosimilars portfolio. This portfolio will encompass therapeutic areas such as oncology, inflammation, and immunology. To support this manufacturing endeavour, Samsung Biologics will utilise its latest facility, known as Plant 4.

Together, this collaboration is poised to make a meaningful impact in the field of biopharmaceutical manufacturing and contribute to improving global healthcare outcomes.

This collaboration signifies a significant step forward in the mutual commitment to meet the growing demand for high-quality biopharmaceuticals on a global scale. 

By leveraging Samsung Biologics' state-of-the-art manufacturing capabilities and Pfizer's expertise in developing innovative therapies, this partnership aims to enhance production efficiency, ensure a stable supply chain, and ultimately deliver life-saving treatments to patients around the world.